SCHEMBL21847115

SCHEMBL21847115

COc1ccc(CN2N=C(c3ccc(Cl)cc3)c3c(sc(C)c3C)-n3c(CO)nnc32)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 20/20 0.44
ADORA3 P0DMS8 1/20 0.44
TSPO P30536 1/20 0.44
BRD2 P25440 4/20 0.41
BRD3 Q15059 3/20 0.41
BRDT Q58F21 3/20 0.41
CREBBP Q92793 2/20 0.41
DNER Q8NFT8 2/20 0.41
HDAC3 O15379 1/20 0.41
JAK2 O60674 1/20 0.41
BRD1 O95696 1/20 0.41
CCL2 P13500 1/20 0.41
HDAC4 P56524 1/20 0.41
EP300 Q09472 1/20 0.41
HDAC1 Q13547 1/20 0.41
HDAC7 Q8WUI4 1/20 0.41
HDAC2 Q92769 1/20 0.41
HDAC10 Q969S8 1/20 0.41
HDAC11 Q96DB2 1/20 0.41
HDAC8 Q9BY41 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8316015 0.89 BRD4 (0.51) BRD4ADORA3TSPOBRD2BRD3
SCHEMBL21847102 0.85 BRD4 (0.42) BRD4ADORA3TSPOBRD2BRD3
SCHEMBL8318059 0.85 BRD4 (0.45) BRD4ADORA3TSPOBRD2BRD3
SCHEMBL8320915 0.82 BRD4 (0.52) BRD4ADORA3TSPOBRD2BRD3
SCHEMBL8320587 0.81 BRD4 (0.45) BRD4ADORA3TSPOBRD2BRD3
SCHEMBL21847157 0.81 BRD4 (0.48) BRD4ADORA3TSPOBRD2BRD3
SCHEMBL8318164 0.80 BRD4 (0.43) BRD4ADORA3TSPOBRD2BRD3
SCHEMBL21847138 0.80 BRD4 (0.46) BRD4ADORA3TSPOBRD2BRD3
SCHEMBL21847110 0.80 BRD4 (0.49) BRD4ADORA3TSPOBRD2BRD3
SCHEMBL8320181 0.79 BRD4 (0.48) BRD4ADORA3TSPOBRDT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210130367-A1 6H-THIENO[2,3-e][1,2,4]TRIAZOLO[3,4-c][1,2,4]TRIAZEPINE DERIVATIVE AYUMI PHARMACEUTICAL CORPORATION (JP) 2021-05-06 US claimed
EP-3640253-A1 6H-THIENO[2,3-E][1,2,4]TRIAZOLO[3,4-C][1,2,4]TRIAZEPINE DERIVATIVE AYUMI Pharmaceutical Corporation (JP) 2020-04-22 EP claimed
US-11186588-B2 6H-thieno[2,3-e][1,2,4]triazolo[3,4-c][1,2,4]triazepine derivative AYUMI PHARMACEUTICAL CORPORATION (JP) 2021-11-30 US disclosed
US-11186588-B2 6H-thieno[2,3-e][1,2,4]triazolo[3,4-c][1,2,4]triazepine derivative AYUMI PHARMACEUTICAL CORPORATION (JP) 2021-11-30 US disclosed
US-20210130367-A1 6H-THIENO[2,3-e][1,2,4]TRIAZOLO[3,4-c][1,2,4]TRIAZEPINE DERIVATIVE AYUMI PHARMACEUTICAL CORPORATION (JP) 2021-05-06 US disclosed
US-20210130367-A1 6H-THIENO[2,3-e][1,2,4]TRIAZOLO[3,4-c][1,2,4]TRIAZEPINE DERIVATIVE AYUMI PHARMACEUTICAL CORPORATION (JP) 2021-05-06 US disclosed
EP-3640253-A1 6H-THIENO[2,3-E][1,2,4]TRIAZOLO[3,4-C][1,2,4]TRIAZEPINE DERIVATIVE AYUMI Pharmaceutical Corporation (JP) 2020-04-22 EP disclosed
EP-3640253-A1 6H-THIENO[2,3-E][1,2,4]TRIAZOLO[3,4-C][1,2,4]TRIAZEPINE DERIVATIVE AYUMI Pharmaceutical Corporation (JP) 2020-04-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210130367-A1 6H-THIENO[2,3-e][1,2,4]TRIAZOLO[3,4-c][1,2,4]TRIAZEPINE DERIVATIVE BRD4, BRD3, BRD2 BRD4 1/4885ADORA3 2499/4885TSPO 923/4885
US-11186588-B2 6H-thieno[2,3-e][1,2,4]triazolo[3,4-c][1,2,4]triazepine derivative BRD4, BRD3, BRD2 BRD4 1/4885ADORA3 2499/4885TSPO 923/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.